Potential therapeutic strategies for BTK/PLCG2 mutated CLL include inhibition of BCL2, disruption of alternate BCR pathway kinases and the use of novel BTK inhibitors which do not rely on the Cys481 residue for binding. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.